Treatment for Health Screening

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Texas Medical Center, Dallas, TX
Health Screening
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new device that may help detect heart problems. The study will be conducted on subjects who have been enrolled in prior registry studies. The treatment being trialed is designed to treat health screening and all patients taking part in the trial will receive the active treatment rather than a placebo.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Health Screening

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline

Baseline
Diagnostic Performance

Trial Safety

Safety Progress

1 of 3

Other trials for Health Screening

Trial Design

0 Treatment Group

50 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline
Closest Location: University of Texas Medical Center · Dallas, TX
Photo of university of texas southwestern medical center 1Photo of university of texas southwestern medical center 2Photo of university of texas southwestern medical center 3
2004First Recorded Clinical Trial
1 TrialsResearching Health Screening
4 CompletedClinical Trials

Who is running the clinical trial?

Heart Test Laboratories, Inc.Lead Sponsor
3 Previous Clinical Trials
975 Total Patients Enrolled
Partho Sengupta, MDPrincipal InvestigatorRutgers Robert Wood Johnson Medical School
4 Previous Clinical Trials
1,398 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Subjects will be recruited from the existing registry studies within the institution.
The subject provides written informed consent using an Informed Consent Form that is reviewed and approved by the site's IRB.
You have a sinus rhythm and no other contraindicated rhythm abnormalities.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.